Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
Title
Type
[
Year
]
Filters:
Author
is
O'Brien, Susan M
[Clear All Filters]
2020
Jabbour E
,
Richard-Carpentier G
,
Sasaki Y
,
Konopleva M
,
Patel K
,
Roberts K
,
Gu Z
,
Wang F
,
Huang X
,
Sasaki K
, et al.
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.
Lancet Haematol. 2020;7(7):e523-e533.
PubMed
Google Scholar
2019
Kantarjian HM
,
DeAngelo DJ
,
Stelljes M
,
Liedtke M
,
Stock W
,
Gökbuget N
,
O'Brien SM
,
Jabbour E
,
Wang T
,
White JLiang
, et al.
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
Cancer. 2019.
PubMed
Google Scholar
2016
Chiaretti S
,
Gianfelici V
,
O'Brien SM
,
Mullighan CG
.
Advances in the Genetics and Therapy of Acute Lymphoblastic Leukemia.
Am Soc Clin Oncol Educ Book. 2016;35:e314-e322.
PubMed
Google Scholar
Jabbour E
,
Short NJ
,
Jorgensen JL
,
Yilmaz M
,
Ravandi F
,
Wang SA
,
Thomas DA
,
Khoury J
,
Champlin RE
,
Khouri I
, et al.
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Cancer. 2016.
PubMed
Google Scholar
Short NJ
,
Kantarjian HM
,
Sasaki K
,
Cortes JE
,
Ravandi F
,
Thomas DA
,
Garcia-Manero G
,
Khouri I
,
Kebriaei P
,
Champlin RE
, et al.
Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Cancer. 2016.
PubMed
Google Scholar
2015
Ravandi F
,
Jorgensen JL
,
O'Brien SM
,
Jabbour E
,
Thomas DA
,
Borthakur G
,
Garris R
,
Huang X
,
Garcia-Manero G
,
Burger JA
, et al.
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.
Br J Haematol. 2015.
PubMed
Google Scholar